The selection and schedule of treatment should depend on patient preference and toxicity potential, according to Azka Ali, MD.

Researchers conducted an analysis of how NCCN guidelines for myeloma treatment are updated, offering suggestions for a more standardized process.

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease.

Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.

Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.

The prognosis of patients diagnosed with cancer after starting hemodialysis appears comparable to that of patients with cancer in the general population.

Phase 3 data support pyrotinib plus trastuzumab and docetaxel “as a well-established and effective treatment strategy,” according to Binghe Xu, MD.

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Researchers sought to determine the efficacy of a support program for patients with advanced cancer and their spouses who had minor children.

Modest absolute reduction in use observed, which increased during peak of shortage; no difference seen in mortality during shortage.